Clinical Trial: Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer

U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07635290) titled 'Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer' on June 03.

Brief Summary: This study aims to evaluate the safety and preliminary efficacy of anlotinib combined with cadonilimab and PULSAR in previously treated advanced unresectable or netastatic biliary tract cancer.

Study Start Date: June 03

Study Type: INTERVENTIONAL

Condition: Previously Treated, Advanced Biliary Tract Cancers

Intervention: DRUG: Anlotinib + Cadonilimab

Anlotinib Combined with Cadonilimab

RADIATION: PULSAR

Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy

Recruitment Status: ACTIVE_NOT_RECRUITING

Sponsor: West China Hos...